---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-188977"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:24:23.087115+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PepGen announces positive Phase 2 data for PGN-EDO51 in DMD: exon skipping 2.15%, dystrophin increase

## Summary
- PGN-EDO51 5 mg/kg achieved mean exon skipping of 2.15% in biceps tissue at week 13 (n=3).
- Mean muscle-adjusted dystrophin level of 1.49% of normal, +0.70% from baseline; absolute dystrophin 0.61%, +0.26%.
- Drug well tolerated; no discontinuations, one mild AE resolved, no kidney or electrolyte issues.
- All three patients continue in long-term extension; 10 mg/kg cohort dosing ongoing with results expected in early 2025.
- CONNECT2 Phase 2 trial open in UK; US site expected by year-end; design being optimized based on data.

## SEC filing metadata
- accession: 0001193125-24-188977
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312524188977/0001193125-24-188977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312524188977/d879173d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-188977
- JSON: https://secwatch.observer/filing/0001193125-24-188977.json
- Plain text: https://secwatch.observer/filing/0001193125-24-188977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.